Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 5/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2146984 | 1.00 | KDM1A (0.42) | KDM1AMAOBSIGMAR1TSHRALDH1A1 | |
| SCHEMBL5960895 | 1.00 | KDM1A (0.42) | KDM1AMAOBSIGMAR1TSHRALDH1A1 | |
| SCHEMBL29453777 | 1.00 | KDM1A (0.42) | KDM1AMAOBSIGMAR1TSHRALDH1A1 | |
| Hydrochloric Acid SCHEMBL1970466 | 0.98 | KDM1A (0.41) | KDM1AMAOBSIGMAR1TSHRALDH1A1 | |
| Hydrochloric Acid SCHEMBL27310401 | 0.98 | KDM1A (0.41) | KDM1AMAOBSIGMAR1TSHRALDH1A1 | |
| SCHEMBL2325227 | 0.90 | KDM1A (0.47) | KDM1ASIGMAR1TSHRTP53CYP1A2 | |
| SCHEMBL301710 | 0.89 | MAOB (0.43) | KDM1AMAOBSIGMAR1KMT2A | |
| Cadaverine Tartrate SCHEMBL27314718 | 0.86 | KIF11 (0.38) | KDM1AMAOB | |
| SCHEMBL7369496 | 0.79 | KDM1A (0.46) | KDM1AHTR2A | |
| SCHEMBL17603684 | 0.78 | KDM1A (0.47) | KDM1AMAOBSIGMAR1TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102791258-B | Alleviating prolongation delivery formulations of Rasagiline and application thereof | 图必制药公司 | 2018-05-08 | — | — | CN | claimed |
| EP-2796130-A2 | Immediate release tablets of rasagiline hemitartrate | Galenicum Health S.L. (ES) | 2014-10-29 | — | — | EP | claimed |
| EP-2766007-A1 | RASAGILINE CITRAMIDE | Teva Pharmaceutical Industries Ltd. (IL) | 2014-08-20 | — | — | EP | claimed |
| EP-2766004-A1 | R(+)-N-METHYL-PROPARGYL-AMINOINDAN | Teva Pharmaceuticals USA, Inc. (US) | 2014-08-20 | — | — | EP | claimed |
| EP-2766002-A2 | R(+)-N-FORMYL-PROPARGYL-AMINOINDAN | Teva Pharmaceutical Industries Ltd. (IL) | 2014-08-20 | — | — | EP | claimed |
| EP-2688561-A2 | TRANSDERMAL COMPOSITIONS COMPRISING AN ACTIVE AGENT LAYER AND AN ACTIVE AGENT CONVERSION LAYER | Teikoku Pharma USA, Inc. (US) | 2014-01-29 | — | — | EP | claimed |
| CN-101557706-B | Crystalline solid rasagiline base | TEVA PHARMA | 2013-08-07 | — | — | CN | claimed |
| EP-2603212-A1 | USE OF RASAGILINE FOR THE TREATMENT OF OLFACTORY DYSFUNCTION | Teva Pharmaceutical Industries Ltd. (IL) | 2013-06-19 | — | — | EP | claimed |
| CN-103142570-A | Use of low-dose Ladostigil for neuroprotection | YISSUM RES DEV CO (IL) | 2013-06-12 | — | — | CN | claimed |
| WO-2013055687-A2 | R(+)-N-FORMYL-PROPARGYL-AMINOINDAN | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2013-04-18 | — | — | WO | claimed |
| EP-0966435-A1 | AMINOINDAN DERIVATIVES | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1999-12-29 | — | — | EP | claimed |
| EP-0929298-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING S-(-)-N-PROPARGYL-1-AMINO INDAN | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1999-07-21 | — | — | EP | claimed |
| EP-0828485-A4 | USE OF R-ENANTIOMER OF N-PROPARGYL-1-AMINOINDAN, SALTS, AND COMPOSITIONS THEREOF | TEVA PHARMA (IL) | 1998-12-02 | — | — | EP | claimed |
| WO-1998027055-A1 | AMINOINDAN DERIVATIVES | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1998-06-25 | — | — | WO | claimed |
| EP-0828485-A1 | USE OF R-ENANTIOMER OF N-PROPARGYL-1-AMINOINDAN, SALTS, AND COMPOSITIONS THEREOF | Teva Pharmaceutical Industries, Inc. (IL) | 1998-03-18 | — | — | EP | claimed |
| EP-0812190-A4 | R-ENANTIOMER OF N-PROPARGYL-1-AMINOINDAN, SALTS, COMPOSITIONS AND USES THEREOF | TEVA PHARMA (IL) | 1998-03-04 | — | — | EP | claimed |
| WO-1998002152-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING S-(-)-N-PROPARGYL-1-AMINO INDAN | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1998-01-22 | — | — | WO | claimed |
| EP-0812190-A1 | R-ENANTIOMER OF N-PROPARGYL-1-AMINOINDAN, SALTS, COMPOSITIONS AND USES THEREOF | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1997-12-17 | — | — | EP | claimed |
| WO-1996037199-A1 | USE OF R-ENANTIOMER OF N-PROPARGYL-1-AMINOINDAN, SALTS, AND COMPOSITIONS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1996-11-28 | — | — | WO | claimed |
| WO-1995011016-A1 | R-ENANTIOMER OF N-PROPARGYL-1-AMINOINDAN, SALTS, COMPOSITIONS AND USES THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1995-04-27 | — | — | WO | claimed |